Seoul National University Hospital

Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021.

Huonslab has completed patient enrollment in its pivotal Phase 1 clinical trial of HLB3-002 (Hydizyme™), a recombinant human hyaluronidase, with 243 healthy volunteers across four leading South Korean medical centers.

GV1001, developed by GemVax & KAEL, has received both FDA Fast Track designation and Korean Ministry of Food and Drug Safety approval for therapeutic use in progressive supranuclear palsy patients.

Hanmi Pharmaceutical has entered a Clinical Trial Collaboration and Supply Agreement with MSD to evaluate its novel immunotherapy BH3120 in combination with KEYTRUDA for patients with progressive or metastatic solid tumors.